Alzheimer Disease Clinical Trial
Official title:
Transcranial Magnetic Stimulation (TMS) and Lithium Water for Treatment of Alzheimer Patients
The thermal therapy combined with magnetic fields and ozone has a direct effect on patients with dementia and Alzheimer's with a regression of more than 60% of them
Alzheimer's disease (AD) is the leading cause of dementia and cognitive deteriorating in the
advanced age. This main target of this study is to determine the safety and efficacy of
transcranial magnetic stimulation (TMS) using novel coil design (H2) for stimulation of deep
brain structures concomitantly with regular treatment in Alzheimer's disease (AD) patients.
TMS acts by generating magnetic fields in the brain which simulate neuro-chemical changes
and stimulate neuronal activity translating into increased secretion of growth factors such
as brain derived neurotropic factor (BDNF). Hence it is postulated that TMS will have a
positive effect on the cognitive and behavioral symptoms of patients with AD and may
ameliorated the progression of the disease. The treatment is non-invasive, with no
significant side effects, and no need of hospitalization or anesthesia. The trial is phase
II double blind study including 100 AD patients ages between 50 to 80 with mild or moderate
AD (Mini Mental State Examination [MMSE] 16 to 26) divided into 3 groups. All participants
will receive standard medical therapy for AD. In addition, patients recruited for the study
will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive
excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group
will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients
will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in
the first 3 weeks and then 1 treatment per week for additional 4 weeks. Patients will be
evaluated before the treatments, after 8 weeks of treatment and after another 8 weeks
without treatment. The evaluations will include cognitive function according to ADAS-COG and
MMSE, Activity of daily living (ADL) functions according to ADSC-ADL, behavioral function
according to the Neuropsychiatric Inventory (NPI), depression according to the Cornell Scale
for Depression in Dementia (CSDD), care giver satisfaction according to the RUD LITE scale
and computerized cognitive evaluation according to the NEXING battery. We expect that the
cognitive, behavioral and ADL functions will improve better in the study group as compared
to the Sham treated group. From previous trial of TMS in neurological patients, although not
in AD, we anticipate that adverse events rate will be similar between groups proving the
safety of deep TMS treatment in patients with AD. In case our hypothesis will be proven,
deep TMS treatment will be added as an important modality to the conventional therapy of AD
patients.
All patients will be received 500 mcg/d of lithium as supplement nutritional in form spring
mineral water
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |